Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
2.750
-0.050 (-1.79%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
10.79M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.79M |
| BioLineRx | 1.18M |
| CytoMed Therapeutics | 669.28K |
| Aprea Therapeutics | 285.76K |
| Kiora Pharmaceuticals | 20.00K |
IMNN News
- 4 weeks ago - Imunon Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study - GlobeNewsWire
- 4 weeks ago - IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 5 weeks ago - IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - GlobeNewsWire
- 2 months ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 4 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 4 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 5 months ago - Imunon Earnings Call Transcript: Q3 2025 - Transcripts